Amancio Carnero

List of Publications by Year in Descending Order

182 papers	7,954 citations	43 h-index	83 g-index
192 ext. papers	8,896 ext. citations	6.5 avg, IF	6.29 L-index

#	Paper	IF	Citations
182	SPINOPHILIN: a multiplayer tumor suppressor. *Genes and Diseases*, **2022**,	6.6	
181	3D and organoid culture in research: physiology, hereditary genetic diseases and cancer.. *Cell and Bioscience*, **2022**, 12, 39	9.8	2
180	Regulation of sarcomagenesis by the empty spiracles homeobox genes EMX1 and EMX2. *Cell Death and Disease*, **2021**, 12, 515	9.8	4
179	Cellular senescence or stemness: hypoxia flips the coin. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 243	12.8	3
178	Mutation of SPINOPHILIN (PPP1R9B) found in human tumors promotes the tumorigenic and stemness properties of cells. *Theranostics*, **2021**, 11, 3452-3471	12.1	1
177	NAD metabolism, stemness, the immune response, and cancer. *Signal Transduction and Targeted Therapy*, **2021**, 6, 2	21	43
176	Empty spiracles homeobox genes EMX1 and EMX2 regulate WNT pathway activation in sarcomagenesis. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 247	12.8	1
175	Leveraging Genomics, Transcriptomics, and Epigenomics to Understand the Biology and Chemoresistance of Ovarian Cancer. *Cancers*, **2021**, 13,	6.6	3
174	Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. *Cells*, **2020**, 9,	7.9	16
173	FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. *EBioMedicine*, **2020**, 53, 102683	8.8	7
172	Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness. *Molecular Cancer*, **2020**, 19, 7	42.1	26
171	The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness. *Cancers*, **2020**, 12,	6.6	7
170	PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208. *Cells*, **2020**, 9,	7.9	2
169	Implications of maraviroc and/or rapamycin in a mouse model of fragility. *Aging*, **2020**, 12, 8565-8582	5.6	3
168	Role of Mitochondria in Cancer Stem Cell Resistance. *Cells*, **2020**, 9,	7.9	30
167	Breast tumor cells promotes the horizontal propagation of EMT, stemness, and metastasis by transferring the MAP17 protein between subsets of neoplastic cells. *Oncogenesis*, **2020**, 9, 96	6.6	5
166	Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment. *Signal Transduction and Targeted Therapy*, **2020**, 5, 195	21	6

165	Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness. *Frontiers in Oncology*, **2020**, 10, 1533	5.3	7
164	Combined MEK and PI3K/p110□Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. *Cancer Research*, **2020**, 80, 843-856	10.1	10
163	Tumor Profiling at the Service of Cancer Therapy. *Frontiers in Oncology*, **2020**, 10, 595613	5.3	2
162	New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 234	12.8	16
161	c-MYB- and PGC1a-dependent metabolic switch induced by MYBBP1A loss in renal cancer. *Molecular Oncology*, **2019**, 13, 1519-1533	7.9	9
160	NAMPT as a Dedifferentiation-Inducer Gene: NAD as Core Axis for Glioma Cancer Stem-Like Cells Maintenance. *Frontiers in Oncology*, **2019**, 9, 292	5.3	15
159	FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. *Journal of Thoracic Oncology*, **2019**, 14, 641-655	8.9	29
158	FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. *Lung Cancer*, **2019**, 131, 112-121	5.9	9
157	Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. *Cells*, **2019**, 8,	7.9	1
156	Loss of MYBBP1A Induces Cancer Stem Cell Activity in Renal Cancer. *Cancers*, **2019**, 11,	6.6	9
155	Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment. *Oncogene*, **2019**, 38, 1309-1323	9.2	17
154	The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. *Scientific Reports*, **2018**, 8, 2394	4.9	22
153	Dr. Jekyll and Mr. Hyde: MAP17ʦ up-regulation, a crosspoint in cancer and inflammatory diseases. *Molecular Cancer*, **2018**, 17, 80	42.1	9
152	MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. *Journal of Experimental and Clinical Cancer Research*, **2018**, 37, 195	12.8	16
151	Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP. *Clinical Cancer Research*, **2018**, 24, 1202-1215	12.9	69
150	Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer. *Oncotarget*, **2018**, 9, 4395-4410	3.3	27
149	NUMB and NUMBL differences in gene regulation. *Oncotarget*, **2018**, 9, 9219-9234	3.3	5
148	Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer. *Oncotarget*, **2018**, 9, 19945-19960	3.3	5

147	MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy. *Oncotarget*, **2018**, 9, 32958-32971	3.3	11
146	Synthesis, Reactivity Studies, and Cytotoxicity of Two trans-Iodidoplatinum(II) Complexes. Does Photoactivation Work?. *Inorganics*, **2018**, 6, 127	2.9	2
145	The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. *Clinical Cancer Research*, **2017**, 23, 3871-3883	12.9	36
144	Prognostic relevance of Src activation in stage II-III colon cancer. *Human Pathology*, **2017**, 67, 119-125	3.7	9
143	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). *Annals of Oncology*, **2017**, 28, 2994-2999	10.3	33
142	NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis. *Oncotarget*, **2017**, 8, 99514-99530	3.3	39
141	The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment. *Oncotarget*, **2017**, 8, 98580-98597	3.3	13
140	Genome-Wide miRNA Screening for Genes Bypassing Oncogene-Induced Senescence. *Methods in Molecular Biology*, **2017**, 1534, 53-68	1.4	1
139	Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus. *Oncotarget*, **2017**, 8, 58872-58886	3.3	19
138	Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer. *Oncotarget*, **2017**, 8, 105196-105210	3.3	9
137	Numb-like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy. *Oncotarget*, **2016**, 7, 63611-63628	3.3	32
136	IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF). *Journal of Thoracic Oncology*, **2016**, 11, 2183-2192	8.9	16
135	A genetic view of laryngeal cancer heterogeneity. *Cell Cycle*, **2016**, 15, 1202-12	4.7	21
134	Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors. *Oncogene*, **2016**, 35, 2777-88	9.2	24
133	Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). *Oncotarget*, **2016**, 7, 67033-67046	3.3	19
132	Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival. *Oncotarget*, **2016**, 7, 31723-37	3.3	13
131	Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. *Oncotarget*, **2016**, 7, 33111-24	3.3	22
130	The cancer stem-cell signaling network and resistance to therapy. *Cancer Treatment Reviews*, **2016**, 49, 25-36	14.4	98

129	The role of PIM1/PIM2 kinases in tumors of the male reproductive system. *Scientific Reports*, **2016**, 6, 38079	4.9	19
128	The hypoxic microenvironment: A determinant of cancer stem cell evolution. *BioEssays*, **2016**, 38 Suppl 1, S65-74	4.1	125
127	Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy. *BMC Cancer*, **2016**, 16, 829	4.8	0
126	The Cytoskeletal Adapter Protein Spinophilin Regulates Invadopodia Dynamics and Tumor Cell Invasion in Glioblastoma. *Molecular Cancer Research*, **2016**, 14, 1277-1287	6.6	18
125	The hypoxic microenvironment: A determinant of cancer stem cell evolution. *Inside the Cell*, **2016**, 1, 96-105		4
124	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. *Carcinogenesis*, **2015**, 36 Suppl 1, S254-96	4.6	176
123	Senescence in Oncogenesis: From Molecular Mechanisms to Therapeutic Opportunities **2015**, 127-155		
122	Disruptive chemicals, senescence and immortality. *Carcinogenesis*, **2015**, 36 Suppl 1, S19-37	4.6	26
121	Therapeutic targeting of replicative immortality. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S104-S128	12.7	40
120	MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFB Activation in Breast Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 1454-65	6.1	22
119	Designing a broad-spectrum integrative approach for cancer prevention and treatment. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S276-S304	12.7	179
118	Genetic modification of hypoxia signaling in animal models and its effect on cancer. *Clinical and Translational Oncology*, **2015**, 17, 90-102	3.6	10
117	Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. *Oncotarget*, **2015**, 6, 6151-9	3.3	17
116	MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer. *Oncotarget*, **2015**, 6, 12625-36	3.3	24
115	High casein kinase 1 epsilon levels are correlated with better prognosis in subsets of patients with breast cancer. *Oncotarget*, **2015**, 6, 30343-56	3.3	6
114	Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. *Oncotarget*, **2015**, 6, 40557-74	3.3	43
113	Decoding Warburg hypothesis: tumor-related mutations in the mitochondrial respiratory chain. *Oncotarget*, **2015**, 6, 41582-99	3.3	34
112	MAP17 as Biomarker for Cancer Treatment. *Biomarkers in Disease*, **2015**, 167-178		

111	Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis. *BMC Cancer*, **2014**, 14, 281	4.8	11
110	MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD. *European Respiratory Journal*, **2014**, 43, 1740-9	13.6	73
109	The PIM family of serine/threonine kinases in cancer. *Medicinal Research Reviews*, **2014**, 34, 136-59	14.4	143
108	Prognostic relevance of estrogen receptor-β Ser167 phosphorylation in stage II-III colon cancer patients. *Human Pathology*, **2014**, 45, 2437-46	3.7	9
107	MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. *BMC Cancer*, **2014**, 14, 656	4.8	55
106	The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. *Frontiers in Oncology*, **2014**, 4, 252	5.3	126
105	MicroRNA-dependent regulation of transcription in non-small cell lung cancer. *PLoS ONE*, **2014**, 9, e90524	3.7	53
104	MAP17 as Biomarker for Cancer Treatment **2014**, 1-10		
103	Identification of proteomic signatures associated with lung cancer and COPD. *Journal of Proteomics* , **2013**, 89, 227-37	3.9	94
102	Inhibition of HSP90 molecular chaperones: moving into the clinic. *Lancet Oncology, The*, **2013**, 14, e358-69	21.7	263
101	Proteomic biomarkers in lung cancer. *Clinical and Translational Oncology*, **2013**, 15, 671-82	3.6	21
100	The second generation of iodido complexes: trans-[PtI2(amine)(amine')] bearing different aliphatic amines. *Journal of Inorganic Biochemistry*, **2013**, 127, 182-7	4.2	15
99	Markers of cellular senescence. *Methods in Molecular Biology*, **2013**, 965, 63-81	1.4	50
98	Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs. *Chemical Communications*, **2013**, 49, 4806-8	5.8	20
97	Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. *Biochemical Pharmacology*, **2013**, 85, 629-643	6	111
96	DNA methylation signatures identify biologically distinct thyroid cancer subtypes. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 2811-21	5.6	88
95	Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage. *International Journal of Molecular Sciences*, **2013**, 14, 3440-55	6.3	29
94	Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma. *Clinical Cancer Research*, **2013**, 19, 3925-35	12.9	13

93	Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia. *PLoS ONE*, **2013**, 8, e60277	3.7	22
92	MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. *PLoS ONE*, **2013**, 8, e56169	3.7	38
91	MAP17 and the double-edged sword of ROS. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2012** , 1826, 44-52	11.2	21
90	PDGFRβ and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. *BMC Cancer*, **2012**, 12, 514	4.8	10
89	Association between the miRNA Signatures in Plasma and Bronchoalveolar Fluid in Respiratory Pathologies. *Disease Markers*, **2012**, 32, 221-230	3.2	33
88	p38 limits the contribution of MAP17 to cancer progression in breast tumors. *Oncogene*, **2012**, 31, 4447-59	7.2	25
87	MAP17, a ROS-dependent oncogene. *Frontiers in Oncology*, **2012**, 2, 112	5.3	13
86	The essential role of PIM kinases in sarcoma growth and bone invasion. *Carcinogenesis*, **2012**, 33, 1479-86	4.6	27
85	Spinophilin: a new tumor suppressor at 17q21. *Current Molecular Medicine*, **2012**, 12, 528-35	2.5	15
84	Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. *Disease Markers*, **2012**, 32, 221-30	3.2	23
83	The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity. *Dalton Transactions*, **2011**, 40, 344-7	4.3	28
82	Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. *Cancer Letters*, **2011**, 300, 145-53	9.9	50
81	Cancer, senescence, and aging: translation from basic research to clinics. *Journal of Aging Research*, **2011**, 2011, 692301	2.3	1
80	Epigenetic mechanisms in senescence, immortalisation and cancer. *Biological Reviews*, **2011**, 86, 443-55	13.5	13
79	Down-regulation of spinophilin in lung tumours contributes to tumourigenesis. *Journal of Pathology*, **2011**, 225, 73-82	9.4	15
78	Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. *Cell Cycle*, **2011**, 10, 2751-62	4.7	24
77	Spinophilin loss contributes to tumorigenesis in vivo. *Cell Cycle*, **2011**, 10, 1948-55	4.7	10
76	Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. *Oncogene*, **2010**, 29, 2973-82	9.2	76

75	Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. *PLoS ONE*, **2010**, 5, e9305	3.7	26
74	The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras. *Carcinogenesis*, **2010**, 31, 2145-54	4.6	17
73	Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues. *Molecular Therapy*, **2010**, 18, 936-46	11.7	7
72	The PKB/AKT pathway in cancer. *Current Pharmaceutical Design*, **2010**, 16, 34-44	3.3	230
71	Cellular senescence as a target in cancer control. *Journal of Aging Research*, **2010**, 2011, 725365	2.3	25
70	Bypassing cellular senescence by genetic screening tools. *Clinical and Translational Oncology*, **2010**, 12, 410-7	3.6	23
69	The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine. *European Journal of Medicinal Chemistry*, **2010**, 45, 134-41	6.8	21
68	Understanding FOXO, new views on old transcription factors. *Current Cancer Drug Targets*, **2010**, 10, 135-46	2.8	43
67	Between bench and bed side: PI3K inhibitors. *Current Molecular Pharmacology*, **2010**, 3, 79-90	3.7	1
66	Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. *Journal of Biological Chemistry*, **2009**, 284, 28392-28400	5.4	63
65	Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation. *Molecular and Cellular Biology*, **2009**, 29, 1855-68	4.8	62
64	Using cells devoid of RAS proteins as tools for drug discovery. *Molecular Carcinogenesis*, **2009**, 48, 1038-47	5	6
63	Inhibiting PI3K as a therapeutic strategy against cancer. *Clinical and Translational Oncology*, **2009**, 11, 572-9	3.6	26
62	Adding more content to screening: reactivation of FOXO as a therapeutic strategy. *Clinical and Translational Oncology*, **2009**, 11, 651-8	3.6	4
61	Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators. *BMC Cell Biology*, **2009**, 10, 14		32
60	Novel inhibitors of the PI3K family. *Expert Opinion on Investigational Drugs*, **2009**, 18, 1265-77	5.9	27
59	Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(II) anticancer complexes. *Dalton Transactions*, **2009**, 3457-66	4.3	40
58	Mouse models to decipher the PI3K signaling network in human cancer. *Current Molecular Medicine*, **2009**, 9, 612-25	2.5	18

57	Cellular senescence bypass screen identifies new putative tumor suppressor genes. *Oncogene*, **2008**, 27, 1961-70	9.2	50
56	S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. *Carcinogenesis*, **2008**, 29, 2089-95	4.6	56
55	Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation. *Cancer Research*, **2008**, 68, 9643-53	10.1	45
54	Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function. *Carcinogenesis*, **2008**, 29, 1343-50	4.6	24
53	Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines. *Molecular Cancer Therapeutics*, **2008**, 7, 2358-66	6.1	24
52	The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. *Current Cancer Drug Targets*, **2008**, 8, 187-98	2.8	557
51	Genetic modelling of the PTEN/AKT pathway in cancer research. *Clinical and Translational Oncology*, **2008**, 10, 618-27	3.6	19
50	Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screening. *ChemBioChem*, **2008**, 9, 2229-37	3.8	63
49	Isolation of an Intermediate in the Platination of p-Nitroacetophenone 4-Methylthiosemicarbazone: Potential Application as an Antitumor Drug. *European Journal of Inorganic Chemistry*, **2008**, 2008, 1183-1187	2.3	14
48	Platinum(IV) Complexes of 3- and 4-Picolinic Acids Containing Ammine or Isopropylamine Ligands Synthesis, Characteri□zation, X-ray Structures, and Evaluation of Their Cytotoxic Activity against Cancer Cell Lines. *European Journal of Inorganic Chemistry*, **2008**, 2008, 4762-4769	2.3	7
47	Influence of (hydroxymethyl)pyridine and pyridine-carboxylic acids, in trans-position to the isopropylamine and amine ligands, on the cytotoxicity of platinum complexes. *Chemistry and Biodiversity*, **2008**, 5, 2090-100	2.5	11
46	PPP1CA contributes to the senescence program induced by oncogenic Ras. *Carcinogenesis*, **2008**, 29, 491-9	4.6	51
45	A dual-color fluorescence-based platform to identify selective inhibitors of Akt signaling. *PLoS ONE*, **2008**, 3, e1823	3.7	15
44	Characterization of the p53 response to oncogene-induced senescence. *PLoS ONE*, **2008**, 3, e3230	3.7	32
43	New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin. *Journal of Medicinal Chemistry*, **2007**, 50, 2194-9	8.3	57
42	Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. *Journal of Cellular Biochemistry*, **2007**, 100, 339-48	4.7	32
41	Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death. *Journal of Inorganic Biochemistry*, **2007**, 101, 551-8	4.2	11
40	An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. *Assay and Drug Development Technologies*, **2007**, 5, 333-41	2.1	33

39	MAP17 overexpression is a common characteristic of carcinomas. *Carcinogenesis*, **2007**, 28, 1646-52	4.6	42
38	MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation. *Carcinogenesis*, **2007**, 28, 2443-50	4.6	29
37	MAP17 enhances the malignant behavior of tumor cells through ROS increase. *Carcinogenesis*, **2007**, 28, 2096-104	4.6	50
36	Levels of p27(kip1) determine Aplidin sensitivity. *Molecular Cancer Therapeutics*, **2007**, 6, 1310-6	6.1	30
35	Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. *Carcinogenesis*, **2007**, 28, 584-94	4.6	42
34	Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. *Carcinogenesis*, **2007**, 28, 1418-25	4.6	19
33	Cellular Senescence as a Target in Cancer Control. *Current Cancer Therapy Reviews*, **2007**, 3, 7-15	0.4	3
32	Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. *Blood*, **2007**, 110, 3345-51	2.2	34
31	PTEN, more than the AKT pathway. *Carcinogenesis*, **2007**, 28, 1379-86	4.6	318
30	High throughput screening in drug discovery. *Clinical and Translational Oncology*, **2006**, 8, 482-90	3.6	65
29	EMX homeobox genes regulate microphthalmia and alter melanocyte biology. *Experimental Cell Research*, **2005**, 311, 27-38	4.2	10
28	Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria. *Anti-Cancer Drugs*, **2005**, 16, 977-87	2.4	17
27	CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. *Oncogene*, **2005**, 24, 5543-51	9.2	136
26	Identification of transcripts specific for physiological gene activation by platelet-derived growth factor (PDGF)-B in intact brain tissue. *Journal of Cellular Biochemistry*, **2005**, 95, 859-67	4.7	1
25	Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. *Journal of Cellular Biochemistry*, **2005**, 95, 979-89	4.7	33
24	Roscovitine targets, protein kinases and pyridoxal kinase. *Journal of Biological Chemistry*, **2005**, 280, 31208-19	5.4	278
23	Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. *Molecular Cancer Therapeutics*, **2005**, 4, 814-23	6.1	49
22	Immortalization of primary human prostate epithelial cells by c-Myc. *Cancer Research*, **2005**, 65, 2179-85	10.1	96

21	Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. *Cancer Research*, **2005**, 65, 3846-52	10.1	47
20	Glycolytic enzymes can modulate cellular life span. *Cancer Research*, **2005**, 65, 177-85	10.1	450
19	Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation. *Oncogene*, **2004**, 23, 6006-11	9.2	35
18	Cellular senescence induced by p53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. *Journal of Cellular Biochemistry*, **2004**, 92, 514-24	4.7	19
17	Non-neutral role of replicative senescence in tissue homeostasis and tumorigenesis. *Journal of Theoretical Biology*, **2004**, 230, 333-41	2.3	5
16	Overexpression of cyclin D1 inhibits TNF-induced growth arrest. *Journal of Cellular Biochemistry*, **2003**, 89, 484-99	4.7	10
15	Exploring cellular senescence as a tumor suppressor mechanism **2003**, 5, 249-265		2
14	Cell cycle deregulation: a common motif in cancer. *Progress in Cell Cycle Research*, **2003**, 5, 5-18		58
13	p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. *Nature Cell Biology*, **2000**, 2, 148-55	23.4	247
12	Cell cycle and cancer **2000**, 2, 12-22		1
11	MaRX: an approach to genetics in mammalian cells. *Science*, **1999**, 283, 1129-30	33.3	87
10	A proinflammatory cytokine inhibits p53 tumor suppressor activity. *Journal of Experimental Medicine*, **1999**, 190, 1375-82	16.6	482
9	Wortmannin, an inhibitor of phosphatidyl-inositol 3-kinase, induces oocyte maturation through a MPF-MAPK-dependent pathway. *FEBS Letters*, **1998**, 422, 155-9	3.8	15
8	Rho proteins induce metastatic properties in vivo. *Oncogene*, **1997**, 15, 3047-57	9.2	142
7	Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes. *International Journal of Cancer*, **1995**, 60, 235-43	7.5	24
6	ras-p21 activates phospholipase D and A2, but not phospholipase C or PKC, in Xenopus laevis oocytes. *Journal of Cellular Biochemistry*, **1994**, 54, 478-86	4.7	31
5	Progesterone but not ras requires MPF for in vivo activation of MAPK and S6 KII: MAPK is an essential conexion point of both signaling pathways. *Journal of Cellular Biochemistry*, **1994**, 55, 465-76	4.7	18
4	Microinjection of acylphosphatase blocks Xenopus laevis oocytes maturation induced by ras-p21. *FEBS Letters*, **1993**, 326, 167-70	3.8	5

3	Phospholipase-induced maturation of Xenopus laevis oocytes: mitogenic activity of generated metabolites. *Journal of Cellular Biochemistry*, **1993**, 52, 440-8	4.7	25
2	Acylphosphatase synergizes with progesterone during maturation of Xenopus laevis oocytes. *FEBS Letters*, **1993**, 327, 265-70	3.8	5
1	PI3K pathway in cancer193-203		